SOURCE: Nutra Pharma Corp.

Nutra Pharma Corp.

December 17, 2014 08:30 ET

Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders

Nutra Pharma Is Announcing the Delivery and First Shipments of Their New Homeopathic Formula for the Treatment of Chronic Pain in Companion Animals, Pet Pain-Away™

CORAL SPRINGS, FL--(Marketwired - Dec 17, 2014) - Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away™. The Company also announced that they have begun shipping and many distributors have already received their first orders.

"Most of the pain-relieving drugs currently available for both the human and animal markets have severe side effects that may include gastrointestinal difficulties, kidney issues and narcotic problems," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "Pet Pain-Away is a revolutionary new product that promises to change the way we deal with pet pain. It is an easy to use oral gel that pets love and it has none of the side effects associated with other analgesics," he continued. "We also know that Americans are apt to spend more on their pets than themselves, especially in indications of comfort and pain. We are especially pleased with the reception from the distributors and the creation of their website at http://www.petpainaway.com," he concluded.

Pet Pain-Away™ is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.

According to The Humane Society there are 75 million dog owners and 85 million cat owners in the US. These companion animals are as susceptible as humans to ailments that require pain-relieving solutions. The total market for companion animals in the US reached an estimated $58 billion in 2014. Of these expenditures, over $13 billion was spent on medication for the animals. Additionally, a 2009 survey conducted by Virbac Pharmaceuticals puts the annual US market for companion animal pain relievers at more than $250 million.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brand Nyloxin®. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.Nyloxin.com.

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's rollout of Pet Pain-Away should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information